Pregledni rad
PHARMACOLOGY OF BIOLOGIC MEDICATIONS
MARINKO MARUŠIĆ
; Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti Medicinskog fakulteta Sveučilišta u Zagrebu, Klinička bolnica Sveti Duh, Zagreb, Hrvatska
SILVIO MIHALJEVIĆ
; Zavod za gastroenterologiju i hepatologiju,Klinika za unutarnje bolesti Medicinskog fakulteta Sveučilišta Josip Juraj Strossmayer,Klinički bolnički centar Osijek, Osijek, Hrvatska
Sažetak
Two major types of inflammatory bowel diseases (IBD) are Crohn’s disease (CD) and ulcerative colitis (UC). Insights into their pathophysiology and inflammatory cascade have lead to the discovery of medications that can have a selective effect on a particular molecule or signal pathway and correct an imbalance in pro- and anti-inflammatory mediators. The first to be developed were the TNF-antagonists, soluble receptors like etanercept and monoclonal antibodies. Infliximab has been approved worldwide for treatment of moderate to severe and active fistulizing forms of Crohn’s disease, as well as for severe forms of ulcerative colitis in adults who do not react to full and adequate corticosteroid and/or immunosuppressive therapy, i.e. for patients who have problems with or medical contraindications to such therapy and for treatments of severe forms of active disease in children. Adalimumab can be applied in cases when antibodies develop as a reaction to infliximab, leading to reduced drug efficacy and allergic reactions. According to the available data from preclinical tests and earlier phases of clinical tests, potential candidates for new biological medications in treating IBDs are another TNF-antagonist (certolizumab), inhibitors of Th1 polarisation (fontolizumab,ustekinumab) and selective adhesion-molecule inhibitors (natalizumab)
Ključne riječi
biologics; inflammatory bowel diseases; TNF- α antagonists
Hrčak ID:
111621
URI
Datum izdavanja:
28.11.2013.
Posjeta: 3.174 *